Advanced Practice Providers

Adverse Event Management

Brain Cancer

Breast Cancer

Childhood/AYA Cancer

Disparities in cancer care

Drug Safety

Gastrointestinal Cancer

Genetics

Genitourinary Cancer

Gynecologic Cancers

Head and Neck Cancers

Hematology

Immuno-Oncology

Lung Cancer

Nurse Navigation

Prevention

Radiation Oncology

Sarcomas

Skin Cancer/Melanoma

Supportive Care

Survivorship

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies 

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium 

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer

News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

Webinars

Subscribe

Partners

Articles

Patients with multiple myeloma who received subcutaneous daratumumab experienced reduced clinic times compared with those who received the agent intravenously.

Subcutaneous Administration of Daratumumab Reduces Time in Clinic Vs Intravenous Treatment

Vorasidenib met its prespecified progression-free survival endpoint in the phase 3 INDIGO trial.

Vorasidenib Garners PFS Improvement For Patients With IDH1/2-Mutant Low-Grade Glioma

Heather Simonsen, MA, outlines some ways for health care professionals to feel more comfortable in the spotlight. 

5 Media Tips and Tricks For Health Care Professionals 

Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour. 

Siltuximab May Be Effective Treatment for CRS/ICANS Following CAR T-Cell Therapy 

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Clinical

Gynecologic Cancer

1rem

, we ring in the New Year 2023 by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information surrounding the approvals, be sure to check out our news coverage below. Other resources can also be found below.

, and for all the engagement in 2022. We look forward to bringing you more oncology news in 2023.

We want to hear from you! Which drugs approved in 2022 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email 

FDA Approves Tebentafusp to Treat HLA-A*02:01 Positive Uveal Melanoma

Cilta-Cel Snags FDA Approval for Relapsed/Refractory Multiple Myeloma

Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC

FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer

FDA OKs Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

FDA Approves Pembrolizumab in MSI H/dMMR Advanced Endometrial Carcinoma

FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Axi-Cel Snags FDA Approval for Second-Line LBCL

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia

FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC

Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma

Crizotinib Approved For ALK+ Inflammatory Myofibroblastic Tumors

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer

FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease

FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid Neoplasms

Durvalumab Plus Gemcitabine/Cisplatin Approved by the FDA for Advanced or Metastatic Biliary Tract Cancers

Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients

Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer

FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements

FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC

Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC

Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer

Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia

Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC

Watch: Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer

Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

Goodwin Provides Nursing Perspective on Recent FDA Approvals in NSCLC

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.  

A Look Back at 2022 FDA Approvals in Oncology

® spoke with Christine Miaskowski, PhD, RN

professor in the Department of Physiological Nursing and Anesthesia at UCSF School of Nursing. Miaskowski discusses results from research which showcases an increased risk of hearing loss among patients who received platinum- or taxane-based cancer treatments. She also discusses the importance of including hearing assessments as a standard of care for survivors.

Top takeaways from the discussion include:

“When we did audio metrically confirmed hearing loss [assessments], we found that between 50% to 70% of survivors had confirmed hearing loss.” 

“It’s really, very surprising because it is a group of patients with very common cancers: breast, lung, gynecologic and GI [gastrointestinal] malignancies.” 

“The good news is that the type of hearing loss these patients experience is amenable to a hearing aid. So, if we can get people tested, and they demonstrate this kind of hearing loss, we can improve their quality of life.” 

“Nurses care about interactions with other people, people’s quality of life, [their] social function… if you've got hearing loss, and you're sitting at a table with people, and you can't hear them, you're not going to be likely to participate.” 

“We don’t even think about [some of] these consequences; in terms of occupation, social gatherings, safety for a child… We really, as nurses, need to be doing something about this.” 

Episode 33: Balancing the Benefit and Toxicity of Cisplatin in Young Children with Cancer

Episode 45: Key Advances in Cancer Survivorship Toxicity Management

Audiological Assessments May Be Vital Component of Cancer Survivorship Care Following Chemotherapy

Hearing Loss Found in Testicular Cancer Survivors After Cisplatin Therapy

Genetic Mutation Could Play Role in Cisplatin-Induced Hearing Loss

Oncology Nursing News® Publication Features

Survivors Need Research-Based Interventions and Stronger Coordination Across Care Continuum

What Are the Needs of Cancer Survivors 5 Years or More After Treatment?

Everyone's Business: Taking Survivorship Care to the Next Level

Heather E. Wheeler Discusses Cisplatin-Induced Hearing Loss

Cheung S, Henderson-Sabes J, Mastick J, et al. Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus. 

. Published online July 27, 2022. doi:10.1136/spcare-2022-003684

Romano A, Capozza MA, Mastrangelo S, et al. Assessment and management of platinum-related ototoxicity in children treated for cancer. 

2020;12(5):1266. doi:10.3390/cancers12051266

Biro K, Noszek L, Prekopp P, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. 

. 2006;70(3):177-184. doi:10.1159/000093776

Cheraghi S, Nikoofar P, Fadavi P, et al. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy

2015;32(7):200. doi:10.1007/s12032-015-0646-3

Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. 

. 2013;34(8):458-469. doi:10.1016/j.tips.2013.05.006

, please consider subscribing to our podcast on Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms, to get a notification every time a new episode is posted. Please take a moment to rate us!

Thanks again for listening to 

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss. 

Are Hearing Tests Necessary For Adult Cancer Survivors?

® spoke with Heidi Donovan, PhD, RN, professor of nursing and medicine, and co-director of the National Center on Family Support, at the University of Pittsburgh. Donovan recently co-led a study evaluating the utility of an online symptom management tool for women with recurrent ovarian cancer.

found that women who used the intervention experienced higher satisfaction with their symptom management.

“[In my opinion] some principles of our intervention are critical and actually overdue in clinical practice for ovarian cancer and other cancers,” she noted, emphasizing the importance of systematic symptom assessment in clinical settings, and enhancing women’s confidence in their ability to manage their symptoms, as well as their confidence communicating these symptoms to their healthcare providers.

“[By systematic] I mean [asking] the same questions repeatedly, over time, in order to pick up on changes that that are affecting patients and on symptoms that are affecting their quality of life, and their ability to function on a day-to-day basis,” she said. “The second principle was really enhancing women's confidence… A lot of what we did in this intervention was try to motivate women to recognize how much [of an] effect their symptoms were [causing] and build their confidence in their ability or their knowledge of things that they could try to get better management.”

Donovan HS, Sereika SM, Wenzel LB, et al. Effects of the WRITE symptoms interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG Oncology/GOG Study (GOG-0259). Published online ahead of print February 7, 2022. 

In this episode of “The Vitals,” Heidi Donovan, PhD, RN, discusses novel symptom management intervention for women with recurrent ovarian cancer.

Bringing a New Approach to Symptom Management in Ovarian Cancer

Courtney R. Arn, APRN-CNP, discusses the recent approval of dostarlimab for patients with mismatch repair–deficient recurrent or advanced endometrial cancer.

Arn Unpacks Dostarlimab Approval for Patients With dMMR Advanced Endometrial Cancer

Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer. 

Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian Cancer

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

Lenvatinib/Pembrolizumab Efficacy Data Holds Up in Updated KEYNOTE-146 Analysis for Advanced Endometrial Carcinoma

Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.

FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer

Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.

Neoadjuvant Pembrolizumab Elicits High Response Among dMMR/MSI-H Solid Tumors

All women with ovarian cancer should receive genetic testing, according to Paula Anastasia, RN, MN, AOCN. However, certain actionable targets may be missed depending on the tests ordered in the clinic.

“When we talk about genetic testing, germline testing, now we want panel testing because in addition to the 

 pathogenic variants, there are other pathogenic variants in that family [such as] 

,” says Anastasia, who notes that for nurses working at institutions without genetic counselors onsite, there are valuable genetic counselor services online, which not only provide tests but help contextualize the results for providers and patients alike.

Anastasia recently gave a talk on PARP inhibitor optimization as part of the 

® to discuss what nurses need to know about this class of agents.

There are 2 approved PARP inhibitors for ovarian maintenance therapy, Anastasia says. However, it is important to determine if a patient has a homologous recombination deficiency (HRD) to see if they are eligible for a PARP inhibitor, she adds, noting that studies have shown that patients with a germline mutation or an HRD-positive tumor have a better clinical benefit with a PARP inhibitor.

Lastly, Anastasia underscores the importance of a patient’s prior adverse effect profile from chemotherapy.

“We want to know: how did patients do with their frontline therapy?” she explains. “Did they require growth factors? Was there dose reduction? Do patients have a history of hypertension, which may indicate whether or not they would tolerate something like niraparib?”

All of these are important considerations, she concludes.

Paula Anastasia, RN, MN, AOCN, underscores the value of genetic testing in personalizing treatment decisions in ovarian maintenance therapy. 

Paula Anastasia Emphasizes Importance of Genetic Testing in Selecting Maintenance Therapy for Ovarian Cancer

Most patients are fit to receive a PARP inhibitor for the treatment of ovarian cancer, according to Paula Anastasia, RN, MN, AOCN; however, certain patients may need to start on a lower dose.

Anastasia, a gynecologic oncology clinical nurse specialist for UCLA Health, recently presented on 

 Anastasia discussed the circumstances in which a patient may not be fit for PARP inhibition, even if it was standard of care.

Patients who have poor performance status, for example, or other comorbidities may require an adjusted dosage. However, it is important to note that lower doses do not translate to sub therapeutic benefit.

Other important considerations include individual adverse event profiles, chemotherapy responses, and whether a patient is able to adhere to the administration guidelines, as these are oral medications.

Anastasia also illuminates the fact that, for many patients, the price of these therapies represents a major barrier to care. “These medications can be very expensive, and I’ve [seen] copays of $0 and I’ve [seen] copays of $5000 to $10,000,” she said.

According to Anastasia, ineligibility because of financial burden is not talked about in regard to PARP inhibitors, and although there are copay assistance programs, they are largely underutilized. She notes that she has been successful in obtaining grants for her patients and that leveraging pharmaceutical companies can be helpful.

“It can sometimes be time consuming, but the copay assistance programs, and access groups will do some of the legwork for us.”

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor. 

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

Starting the conversation is a simple, yet important, step to draw attention to DEI—diversity, equity, and inclusion—in oncology nurse leadership, according to Aliènne Salleroli, MS, BSN, RN, OCN.

Salleroli, an assistant patient services manager at Yale-New Haven Health Smilow Cancer Hospital, and cochair of the Yale New Haven Hospital Diversity, Equity, and Inclusion Nursing Task Force, recently spoke on the topic of how racial diversity within oncology leadership is linked with positive outcomes at the 47th Annual Oncology Nursing Society Congress.

®, Salleroli explains that although opening dialogue can be uncomfortable, it yields important results.

“Leadership needs to understand that this is going to be an uncomfortable conversation and part of leadership is becoming comfortable with the uncomfortable,” she said. “But having these conversations [is] actually what bridge[s] that gap. Discussing things like micro-aggressions, implicit biases, language being used… that’s what brings [individuals] together.”

Open dialogue is key to establishing unity across an organization, Salleroli said, adding that these conversations can also inspire local change. For example, once leadership starts the conversation, heads of other teams can bring that information down to their home departments and perpetuate a domino effect.

“We need to walk before we can run,” she concluded.

Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership. 

Aliènne Salleroli on Starting the DEI Conversation in Oncology Nursing

Courtney Arn, APRN-CNP, a nurse practitioner in the Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) advanced endometrial carcinoma.

On March 21, 2022, the FDA approved pembrolizumab monotherapy to treat patients with MSI-H or dMMR advanced endometrial carcinoma. This approval provides patients with an effective treatment option with manageable toxicity, according to Arn.

Courtney Arn, APRN-CNP, a nurse practitioner comments on the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.

Gynecologic Cancers

Latest Conference Coverage